LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Open

SectorGezondheidszorg

18.87 -1.67

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.65

Max

19.26

Belangrijke statistieken
By Trading Economics
Inkomsten	2M -17M
Verkoop	178K 264K
EPS	-0.29
Winstmarge	-6,603.409
Werknemers	116
EBITDA	-2M -21M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+55.52% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-179M 958M
Vorige openingsprijs	20.54
Vorige sluitingsprijs	18.87

Nieuwssentiment

By Acuity

84%

16%

336 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 feb 2026, 22:04 UTC

Winsten

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 23:55 UTC

Marktinformatie

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 feb 2026, 23:37 UTC

Marktinformatie

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 feb 2026, 23:32 UTC

Winsten

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 feb 2026, 23:19 UTC

Acquisities, Fusies, Overnames

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

26 feb 2026, 23:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 feb 2026, 23:01 UTC

Acquisities, Fusies, Overnames

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisities, Fusies, Overnames

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisities, Fusies, Overnames

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 22:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

26 feb 2026, 22:43 UTC

Marktinformatie

RBA Hike In March Is Being Underpriced -- Market Talk

26 feb 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:13 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 feb 2026, 21:59 UTC

Winsten

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 feb 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

26 feb 2026, 21:49 UTC

Winsten

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 21:45 UTC

Winsten

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 feb 2026, 21:44 UTC

Winsten

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 feb 2026, 21:44 UTC

Winsten

Coles Expects Market to Remain Highly Competitive

26 feb 2026, 21:44 UTC

Winsten

Coles Says Supermarket Customers Remain Value Oriented

26 feb 2026, 21:43 UTC

Winsten

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 feb 2026, 21:43 UTC

Winsten

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 feb 2026, 21:42 UTC

Acquisities, Fusies, Overnames

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 feb 2026, 21:41 UTC

Winsten

Acquisities, Fusies, Overnames

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

55.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30 USD 55.52%

Hoogste 30 USD

Laagste 30 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

336 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.